Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.53 |
| ▸ | CCNK | O75909 | 3/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145115 | 0.93 | HCRTR1 (0.56) | HCRTR1HCRTR2CCNKCDK12GFER | |
| SCHEMBL20144970 | 0.88 | HCRTR1 (0.52) | HCRTR1HCRTR2CCNKCDK12GFER | |
| SCHEMBL20144789 | 0.87 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL18697684 | 0.87 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL20144927 | 0.86 | HCRTR1 (0.70) | HCRTR1HCRTR2CCNKCDK12GFER | |
| SCHEMBL20145009 | 0.83 | GFER (0.49) | HCRTR1HCRTR2CCNKCDK12GFER | |
| SCHEMBL20144876 | 0.81 | HCRTR1 (0.69) | HCRTR1HCRTR2 | |
| SCHEMBL16149117 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2 | |
| SCHEMBL20144983 | 0.79 | HCRTR1 (0.52) | HCRTR1HCRTR2CCNKCDK12 | |
| SCHEMBL20145164 | 0.79 | HCRTR1 (0.52) | HCRTR1HCRTR2CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |